Form 10-Q · Quarterly report
Vertex Pharmaceuticals 10-Q, filed Aug 4, 2026
- Filed
- CIK
- 0000875320
- Accession no.
- 0000875320-26-000259
Summary
Vertex Pharmaceuticals reported second-quarter 2026 total revenues of $3.3 billion, up from $3.0 billion in the same quarter of 2025, and disclosed a July agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, an equity value of about $10.0 billion, expected to close in the third quarter of 2026. The company also said the FDA accepted its biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy with a PDUFA target action date of November 30, 2026, and approved CASGEVY for children two years and older with sickle cell disease or transfusion-dependent beta thalassemia.
Key points
- Vertex recorded $76.4 million of CASGEVY product revenues in Q2 2026, a 151% increase over Q2 2025, and $49.6 million of JOURNAVX revenues, a more than 300% increase.
- Vertex secured reimbursement for ALYFTREK in four additional countries in Q2 2026, including Spain, bringing the total to 25 countries.
- Vertex completed the Phase 2B portion of the OLYMPUS trial of povetacicept in primary membranous nephropathy and confirmed the Phase 3 dose selection.
- The FDA cleared an Investigational New Drug application for VX-017, a stem cell-derived islet cell therapy for type 1 diabetes, with a Phase 1/2 trial planned.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion OVERVIEW We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have seven approved medicines: five that treat the underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, one that treats severe sickle cell disease (“SCD”) and transfusion dependent beta thalassemia (“TDT”), life shortening inherited blood disorders, and one that treats moderate-to-severe acute pain. We are also preparing for the anticipated launch of povetacicept, a potential treatment for IgA nephropathy (“IgAN”). …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.